MannaResearch Acquires Montreal Clinical Research Center
News Jul 12, 2013
MannaResearch announces the successful acquisition of Kells Medical Research Group, a Montreal-based clinical investigator site.
This acquisition represents the fourth Canadian research center MannaResearch has acquired in the past 15 months and its first in Montreal. With more than 15 years of clinical trial experience, Kells Medical Research Group is one of Montreal’s largest primary care research centers and has a database of more than 200,000 patients. The acquisition brings the MannaResearch patient database to 350,000.
Dr. Graham Wood, MannaResearch’s Chief Executive Officer, explains, “Within the industry, the Kells name is synonymous with quality and experience, making the company a perfect fit for MannaResearch. This acquisition represents a strategic addition to our rapidly expanding group of sites, helping us attain our goal of simplifying clinical research in Canada for pharmaceutical companies.”
The acquisition supports MannaResearch’s commitment to growth. Over the next few years MannaResearch plans to add additional research sites within Canada to provide its clients access to consistent, high-quality research centers across the nation.
A form of the hallucinogenic party drug ketamine has cleared one of the final hurdles toward clinical use as an antidepressant. During a meeting at the US Food and Drug Administration (FDA) in Silver Spring, Maryland, an independent advisory panel voted 14-2 in favor of recommending a compound known as esketamine for use in treating depression.READ MORE
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019